

Scan here to find out
more about SHIELD™:



 www.bloodbasedscreening.com



Important Safety Information

Shield™ is intended to be complementary to, and not a replacement for, current recommended CRC screening methods. Patients with an abnormal Shield™ result should be referred for a colonoscopy evaluation. A normal Shield™ result does not rule out colorectal cancer and patients should continue participating in guideline recommended screening programs. This test is not cleared or approved by the US FDA.

All images are actor portrayals only.
This material is intended for healthcare professional use only.

MKTAMEA062023_013S



IT'S FINALLY HERE!

THE EASY WAY TO SCREEN FOR COLORECTAL CANCER

Get screened with a simple blood draw



“Colorectal cancer screening is important and Shield™ made it so much easier.”

TRACY C

Small business owner and mother.
Screened with Shield™.



Colorectal cancer screening is easier than ever with Shield™

Simple blood draw



No prep needed



Done in minutes



Get results in as little as 2 weeks



Ask your healthcare provider today how you can screen with no prep in one step





“I want to be around for my family. That’s why I screened with Shield™.”

JOHN G
Proud father and avid golfer.
Screened with Shield™.

Get screened for colorectal cancer to be there for what matters most

Colorectal cancer screening saves lives

75%
of people who die from colorectal cancer aren’t up to date with screening¹



Colorectal cancer is considered the most preventable form of cancer²

5-year survival rate when caught in:^{3,4}



Screen now with Shield™

Ask your healthcare provider today how you can screen with no prep in one step

1. Doubeni CA, Fedewa SA, Levin TR, et al. Modifiable failures in the colorectal cancer screening process and their association with risk of death. *Gastroenterology*. 2019; 156(1):63-74. doi:10.1053/j.gastro. 2018.09.040.
2. Brenner H, Chen C. The colorectal cancer epidemic: challenges and opportunities for primary, secondary and tertiary prevention. *Br J Cancer*. 2018 Oct;119(7):785-792. doi: 10.1038/s41416-018-0264-x. Epub 2018 Oct 4. PMID: 30287914; PMCID: PMC6189125. 3. Colorectal cancer: statistics. *American Society of Clinical Oncology*. Updated January 2021. Accessed May 10, 2021. <https://www.cancer.net/cancer-types/colorectal-cancer/statistics>.
4. Colorectal cancer facts & figures 2017-2019. *American Cancer Society*. Accessed April 20, 2021. <https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/colorectal-cancer-facts-and-figures/colorectal-cancer-facts-and-figures-2017-2019.pdf>





“It’s convenient.
It was an easy decision to choose Shield™.”

RACHEL F

Dog mom and best aunt.
Screened with Shield™.

It’s here: Colorectal cancer screening the way you want it

Shield™ can be completed with a simple blood draw at any doctor visit.


With Shield™, there is:

- ⊘ No preparation
- ⊘ No dietary changes
- ⊘ No sedation
- ⊘ No extra time away from family or work

It’s a no prep, one-step blood draw that’s done in minutes

Shield™ uses a multimodal approach to detect colorectal cancer^{1,2,3,4}

Shield™ assesses for DNA shed by tumours, called circulating tumour DNA (ctDNA), to detect colorectal cancer through a simple blood draw^{4,5}



Shield™ was proven accurate in one of the largest clinical trials of its kind.*

It works by detecting signs of colorectal cancer in blood by looking for DNA shed by tumours.

*In a clinical study with more than 10,000 patients, evaluating Shield™¹ vs colonoscopy for the detection of colorectal cancer in average-risk adults 45-84.^{1,2}

Screen the easy way

Ask your healthcare provider to screen for colorectal cancer with Shield™ today

1. Kim ST, Raymond VM, Park JO, et al. Combined genomic and epigenomic assessment of cell-free circulating tumor DNA (ctDNA) improves assay sensitivity in early-stage colorectal cancer (CRC). *Cancer Res.* 2019;79(suppl 13):916. doi:10.1158/1538-7445.AM2019-916. 2. Westesson O, Axelrod H, Dean J, et al. Integrated genomic and epigenomic cell-free DNA (cfDNA) analysis for the detection of early-stage colorectal cancer. *Cancer Res.* 2020;80(suppl 16):2316. doi:10.1158/1538-7445.AM2020-2316. 3. Data on File. Guardant Health. 4. Lee J, Kim HC, Kim ST, et al. Multimodal circulating tumor DNA (ctDNA) colorectal neoplasia detection assay for asymptomatic and early-stage colorectal cancer (CRC). *J Clin Oncol.* 2021;39(15_suppl):3536. doi:10.1200/jco.2021.39.15_suppl.3536. 5. The genetics of cancer. *American Society of Clinical Oncology.* Updated March 2018. Accessed April 6, 2022. <https://www.cancer.net/navigating-cancer-care/cancer-basics/genetics/genetics-cancer>.

1. Data on File. Guardant Health. 2. Chung, et al. *Digestive Diseases Week 2023.* Abstract #913a.

